Global Hypoparathyroidism Treatment Market Size study, by Product (Parathyroid Hormone, Vitamin D Analogue, Calcium Supplements), by Administration (Oral, Parenteral) and Regional Forecasts 2021-2027

Global Hypoparathyroidism Treatment Market is valued at approximately USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2021-2027. Hypoparathyroidism Treatment is a treatment in which a low level of parathyroid hormone is produced by hypoparathyroidism. Parathyroid hormone maintains and regulates the balance between calcium and phosphorus. Increasing number of thoracic surgeries and incidence of cancer, new drug development and government support have led to the adoption of Hypoparathyroidism Treatment across the forecast period. For Instance: as per the National Cancer Institute in 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. Also, with the increasing adoption of technologically advanced treatment, the adoption & demand for Hypoparathyroidism Treatment is likely to increase the market growth during the forecast period. However, lengthy clinical approval cycles impede the growth of the market over the forecast period of 2021-2027.

The key regions considered for the global Hypoparathyroidism Treatment market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to increasing thyroid-related diseases and increasing initiatives by pharmaceutical organizations to generate novel formulations. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027. Factors such as the presence of generic manufacturers would create lucrative growth prospects for the Hypoparathyroidism Treatment market across Asia-Pacific region.

Major market players included in this report are:
Shire NPS Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited.
Entera Bio Ltd.
Amgen Inc.
Ascendis Pharma A/S
F. Hoffmann-La Roche Ltd
ProLynx, Inc.
Extend Biosciences, Inc.
BionPharma Inc.
F Hoffmann-La Roche Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. 

The detailed segments and sub-segment of the market are explained below: 
By Product:
Parathyroid Hormone
Vitamin D Analogue
Calcium Supplements

By Administration:
Oral
Parenteral

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia 
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027

Target Audience of the Global Hypoparathyroidism Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors